Biosimilar Monoclonal Antibodies Market Booming Biosimilar Monoclonal Antibodies Market: Driven by Chronic Diseases, Aging Population, and Patent Expirations

Biosimilar Monoclonal Antibodies Market worth $ 36.85 Billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biosimilar Monoclonal Antibodies Market- by Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab and Other Pipeline Products), Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders and Other Indication), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1218

According to the latest research by InsightAce Analytic, the global Biosimilar Monoclonal Antibodies market is valued at US$ 4.98 Billion in 2021. It is expected to reach US$ 36.85 Billion by 2030, with a CAGR of 25% during a forecast period of 2024-2031.

Monoclonal antibodies (mAbs) are created by identical immune cell clones stemming from a single parent cell. These clones produce highly comparable antibodies, but biosimilar mAbs are not simply identical copies. Biosimilars are a specific type of biotherapeutic product rigorously evaluated to ensure they match the quality, efficacy, and safety of the existing reference drug. They are complex biological molecules with intricate post-translational modifications and hold promise for treating various inflammatory, chronic, and autoimmune diseases.

The global market for biosimilar mAbs is experiencing significant growth due to several factors. The rising prevalence of chronic illnesses like cancer, kidney failure, and rheumatoid arthritis, coupled with the development of advanced mAbs and an aging population, all contribute to this expansion. Furthermore, the expiration of patents on many established mAbs is expected to create significant opportunities in the coming years. This patent expiry will likely lead to increased demand for mAbs throughout the projected period.

However, the market growth faces challenges as well. Producing biological pharmaceuticals is inherently complex, and experience with clinical trials for biosimilars is still evolving. Additionally, strict government regulations for product approval and a lack of manufacturer knowledge regarding biosimilar regulations and approval processes can hinder market expansion.

This revision clarifies the distinction between mAbs and biosimilars and separates the factors driving market growth from the challenges it faces.

ated to be the major contributor to the Biosimilar Monoclonal Antibodies market over the forecast years. The region's strong growth can be ascribed to increased product approvals, a well-established health care infrastructure, and a favorable reimbursement scenario. In addition,

the Asia Pacific regional market is expected to register significant growth during the estimated period because chronic disease burden, the need for affordable therapies, and government funding for healthcare facility improvements are all on the rise.

Major market players operating in the Biosimilar Monoclonal Antibodies market include
BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.

Recent collaborations and agreements in the market:
• In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support third-party biosimilar development. This collaboration resulted in an integrated solution by two prominent service providers in biosimilar development and GMP manufacturing.

• In February 2021, Mylan (US) introduced Ogivri, a trastuzumab biosimilar. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer, previously sold as Herceptin by Genentech.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1218

Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Product, 2022-2030 (Value US$ Mn)
• Bevacizumab
• Cetuximab
• Ranibizumab
• Denosumab
• Eculizumab
• Infliximab
• Trastuzumab
• Rituximab
• Adalimumab
• Other Pipeline Products

Global Biosimilar Monoclonal Antibodies Market, by Indication, 2022-2030 (Value US$ Mn)
• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Other Indication

Global Biosimilar Monoclonal Antibodies Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada

Europe Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Biosimilar Monoclonal Antibodies market
 To receive an industry overview and future trends of the Biosimilar Monoclonal Antibodies market
 To analyze the Biosimilar Monoclonal Antibodies market drivers and challenges
 To get information on the Biosimilar Monoclonal Antibodies market value (US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Biosimilar Monoclonal Antibodies market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1218

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.